China's National Medical Products Administration accepted the application of Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Jiangsu Aosaikang Pharmaceutical, for the marketing authorization of maltol iron capsules, according to a Shenzhen bourse filing on Tuesday.
Shield TX (UK) developed the drug for the treatment of iron deficiency in adults.
The pharmaceutical company's shares slipped less than 2% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments